Based on the encouraging preclinical data obtained with CAR-T cell therapies directed against CD33, CD123, CLL-1, and FLT3, there is some hope that these approaches will also work in vivo in patients with refractory AML. Here, IL3RA is linked to acute myeloid leukemia.